Use of methotrexate and 5-FU for recurrent head and neck cancer

Cancer Treat Rep. 1982 Nov;66(11):1925-8.

Abstract

Thirty patients with recurrent squamous cell carcinoma of the head and neck were treated with methotrexate (250 mg/m2) followed 1 hour later by 5-FU (600 mg/m2). One patient had a complete response and four had partial responses, for an overall response rate of 16%. The response rate in patients with no prior chemotherapy was 21%. Toxic effects included neutrophenia in ten patients, with one associated death from infection; severe mucositis in three patients; and severe diarrhea in seven patients. Three patients had acute abdominal pain requiring hospitalization, with one associated death. The combination of methotrexate and 5-FU as given in our study was not superior to methotrexate alone and had substantial toxicity.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Carcinoma, Squamous Cell / drug therapy*
  • Clinical Trials as Topic
  • Diarrhea / chemically induced
  • Drug Therapy, Combination
  • Female
  • Fluorouracil / administration & dosage*
  • Fluorouracil / adverse effects
  • Head and Neck Neoplasms / drug therapy*
  • Humans
  • Infections / etiology
  • Male
  • Methotrexate / administration & dosage*
  • Methotrexate / adverse effects
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy*
  • Neutropenia / chemically induced

Substances

  • Fluorouracil
  • Methotrexate